Rchr
J-GLOBAL ID:202101014984640760
Update date: Dec. 05, 2024
IMAMURA Masaru
イマムラ マサル | IMAMURA Masaru
Affiliation and department:
Research theme for competitive and other funds (7):
- 2022 - 2025 メモリー様分化誘導を基盤とした多種類のがんに有効なCAR-NK細胞製剤の新規開発
- 2022 - 2025 メモリー様分化誘導を基盤とした多種類のがんに有効なCAR-NK細胞製剤の新規開発
- 2021 - 2024 安全で有効かつ、いつでも誰でも使えるCAR-NK細胞療法の新規開発
- 2018 - 2021 Development of NK Cell expansion by a novel membrane-bound chimeric cytokine
- 2016 - 2019 Development of Novel Immunotherapy of Cancer: NKp44-based Chimeric Antigen Receptors and Methods for Ex Vivo NK cell Expansion
- 2015 - 2018 Development of a novel chimeric antigen receptor T cell immunotherapy targeting immune checkpoint molecules
- 2009 - 2012 Translational Research on the Use of Genetically Modified HumanNatural Killer Cells for Refractory Leukemia.
Show all
Papers (88):
-
Yugo Kawakami, Masaru Imamura, Chihaya Imai. Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment. International journal of hematology. 2024. 119. 5. 479-480
-
Masaru Imamura, Chansu Shin, Michio Ozeki, Kentaro Matsuoka, Akihiko Saitoh, Chihaya Imai. Regression of kaposiform lymphangiomatosis and chronic disseminated intravascular coagulation after inhaled budesonide-formoterol treatment. Pediatric blood & cancer. 2024. 71. 4. e30907
-
Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, et al. Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features. Current oncology (Toronto, Ont.). 2024. 31. 4. 1831-1838
-
棗田 学, 温 城太郎, 塚本 佳広, 岡田 正康, 大石 誠, 久保 暢大, 申 将守, 今村 勝, 今井 千速, エルナガール・シャヘンダ, et al. がんゲノム医療がもたらす小児脳腫瘍の展開 TP53変異を有する脈絡叢癌培養細胞株の樹立およびマルチオミクス解析. 小児の脳神経. 2023. 48. 2. 156-156
-
Yudai Murayama, Yasushi Kasahara, Nobuhiro Kubo, Chansu Shin, Masaru Imamura, Naoki Oike, Takashi Ariizumi, Akihiko Saitoh, Minori Baba, Tomohiro Miyazaki, et al. NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma. Translational Oncology. 2022. 25. 101521-101521
more...
MISC (8):
-
工藤 耕, 土岐 力, 金崎 里香, 小林 明恵, 佐藤 知彦, 神尾 卓哉, 佐々木 伸也, 今村 勝, 今井 千速, 安藤 久美子, et al. BRAFV600E-positive precursors as molecular markers of bone marrow disease in LCH(和訳中). 日本血液学会学術集会. 2021. 83回. OS2-2
-
笠原 靖史, 久保 暢大, 申 将守, 高地 貴行, 岩渕 晴子, 今村 勝, 今井 千速. NKp44キメラ抗原受容体による新しいがん免疫治療の開発. 日本小児科学会雑誌. 2019. 123. 6. 1062-1062
-
Yasushi Kasahara, Changsu Shin, Takayuki Takachi, Nobuhiro Kubo, Haruko Iwabuchi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai. Adoptive T Cell Immunotherapy Against a Wide Range of Malignancies by Using Chimeric Antigen Receptors with NK cell-like Specificity (NKp44-CAR). PEDIATRIC BLOOD & CANCER. 2017. 64. S22-S22
-
Yasushi Kasahara, Changsu Shin, Sakiko Yoshida, Takayuki Takachi, Nobuhiro Kubo, Haruko Iwabuchi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai. A Novel NKp44-Based Chimeric Antigen Receptor That Targets Multiple Types of Cancer. BLOOD. 2016. 128. 22
-
Yasushi Kasahara, Changsu Shin, Takayuki Takachi, Haruko Iwabuchi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai. Interleukin-21 Gene Transduction in Human Natural Killer Cells Enhances Their Anti-Leukemic Capacity. BLOOD. 2015. 126. 23
more...
Return to Previous Page